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digital images of various areas of the tumor. Determinations of poten-
tial sensitivity or resistance was based on the relative level of compara-
tive IF expression and comparison with an in vitro ﬂuorescent reference 
standard. The criteria for resistance versus susceptible is established 
from the internal comparison for the in vitro studies. Within the eight 
lung cancer cell lines in culture, the comparatively resistant cells 
require 7-10 fold higher drug concentrations for the same cytotoxicity 
(IC50) than the comparatively susceptible cells. The expression levels 
of ERCC-1 and beta-tubulin III correlates well with these requirements 
of drug concentrations for same cytotoxicity (IC50 ) with a Pearson 
coefﬁcient of about 0.9. IF signals exceeding those of the most resistant 
and overexpressing line were considered resistant. Final characteriza-
tion of the tumor was based upon both the ERCC1 and BTUB staining. 
Specimens sensitive to both agents were characterized as sensitive (S), 
all others were considered resistant (R). Laboratory personnel were 
blinded to pt identity and outcomes.
Results: 47 pts were enrolled on the study between 1/2000 and 5/2004. 
All pts have completed therapy. The median overall survival is 29.6 
months and median event free survival is 16.9 months. Specimens 
from 10 pts have been analyzed. 4 were sensitive and 6 resistant. There 
was no difference in event free survival between the S and R groups. 
However, there was a trend (p=.08) towards improved overall survival 
in the S group.
Conclusions: 1. This IF assessement can be rapidly performed on 
parafﬁn blocks and provides a quantitative assessment of ERCC1 and 
BTUBB III expression that is not observer dependent. 2. These very 
preliminary data indicate that ERCC1 and BTUBB III may correlate 
with survival in Stage III NSCLC treated with CMT. Additional data 
will be available by the time of the meeting. 
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Phase 1/2 trial of ABT-751 in combination with pemetrexed vs 
pemetrexed alone in subjects with advanced or metastatic non-
small-cell lung cancer (NSCLC)
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Background: ABT-751 is an orally bioavailable sulfonamide that binds 
to the colchicine site on β-tubulin and inhibits polymerization of micro-
tubules. Pemetrexed (Alimta®) is an antineoplastic agent that interrupts 
cell replication. Both compounds have been evaluated individually in 
advanced NSCLC subjects and in combination in preclinical xenograft 
models.
Methods: The Phase 1 open-label dose escalation portion of the 
study was designed to determine the maximum tolerated dose (MTD) 
and recommended Phase 2 dose (RPTD) of ABT-751 when adminis-
tered with pemetrexed. For each cycle, subjects received 500 mg/m2 
pemetrexed IV on Day 1 and ABT-751 orally QD for 14 consecutive 
days followed by 7 days off drug. Dose levels of ABT-751 began at 
200 mg and escalated in 50 mg increments. Pharmacokinetic sampling 
was performed on Day 1 of Cycle 1. The Phase 2 portion of the study 
was designed to determine the effect of ABT-751 plus pemetrexed on 
progression-free survival.
Results: Nine subjects have been accrued into the Phase 1 portion of 
the study. The MTD and RPTD were determined to be 200 mg of ABT-
751 QD for 14 days. Two of 6 subjects (33%) in the 250 mg cohort 
experienced a dose-limiting toxicity (DLT) (1 grade 3 [CTCAE version 
3.0] neuropathy; 1 grade 5 intestinal infarction, shown by CT scan to be 
consistent with ischemic infarction). Two additional subjects reported 
grade 3 treatment-emergent adverse events (fatigue [2], constipation 
[1], dyspnea [1]), which the investigator considered probably or pos-
sibly related to ABT-751. Preliminary pharmacokinetic results for ABT-
751 after the concomitant administration of ABT-751 and pemetrexed 
were comparable to those after the administration of ABT-751 alone 
in a previous Phase 1 study. Preliminary laboratory data for grade 3/4 
hematologic parameters indicate the incidence of neutropenia was 2/8 
(25%) and thrombocytopenia and anemia were each 0% for subjects 
receiving ABT-751 and pemetrexed. The incidences from the peme-
trexed label are 5% for neutropenia, 2% for thrombocytopenia, and 
8% for anemia. Two subjects had partial responses; 1 conﬁrmed and 1 
unconﬁrmed.
Pharmacokinetic parameters of ABT-751 after single oral dose of ABT-751
 
200 mg ABT-751 
With Pemetrexed
200 mg ABT-751 
Alone#
250 mg ABT-751 
With Pemetrexed##
250 mg ABT-751 
Alone#
N 3 23 5 3
Tmax (h) 0.8 ± 0.3 2.0 ± 1.3 3.2 ± 1.8 1.3 ± 0.6
Cmax (μg/mL) 9.9 ± 9.8 9.1 ± 4.5 8.2 ± 4.2 10.9 ± 3.3
AUC0-8 
(μg*h/mL) 27.2 ± 12.9 33.0 ± 10.1 34.9 ± 15.8 45.5 ± 10.5
#From a previous Phase 1 study M01-303
## One subject had unusually low drug plasma levels, which resulted iin lower means for Cmax and AUC0-8 
for the 250 mg dose.
Conclusions: Both the MTD and RPTD of the combination of ABT-
751 and pemetrexed have been determined. Coadministration of peme-
trexed with ABT-751 does not appear to affect the pharmacokinetic 
proﬁle of ABT-751.
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Randomized phase III Trial comparing three chemotherapy 
regimens in advanced non-small cell lung cancer (NSCLC)
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Background: Lung cancer is the leading cause of cancer related death 
worldwide in both males and females. Despite the poor prognosis of 
patients with advanced NCSLC, treatment with the new generation che-
motherapy agents has improved survival, quality of life and decreased 
toxicity compared to older regimens.
Methods: In this study, patients were randomly assigned to receive 
either paclitaxel 175mg/m2 (day1) or gemcitabine 1,250mg/m2 (days 
1 and 8) both combined with cisplatin 80mg/m2 (day 1) or paclitaxel 
175mg/m2 (day1) combined with gemcitabine 1,250 mg/m2 (days 1 
and 8) as ﬁrst line therapy for stage III b having pleural effusion or 
supraclavicular lymph node metastasis and stage IV NSCLC. Primary 
endpoint was comparison of overall survival for the 3 arms. Secondary 
endpoints included response rate, progression free survival and toxici-
ties.
Results: Sixty two patients (arm A, 19, arm B 23, arm C 20 patients) 
were enrolled. Major clinical characteristics in arm A/B/C were: 
Median age 51, 50, and 47 years, stage IV 14 %, 13 %, and 16 %, 
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performance status 2 was evident in 26.3 %, 26 %, and 5 % respec-
tively. Among all the patients treated the overall response rate (RR) was 
53.2%, 95% conﬁdence interval 40.1-66%. Response rates were 52.6% 
for arm A, 65.2% for arm B, and 40% for arm C.
The median survival times were as follows: Arm A, 9.8 months, arm 
B, 12 months, arm C, 9.2 months. Survival did not differ among the 3 
arms (p=0.42). The one year survival rate was 26.3 %, 34.7 % and 25% 
in groups A, B and C respectively. Survival for two years or more was 
evident in 10.5%, 17.3%, and 5% in group A, B, and C respectively. 
The median time to progression was 5 months for arm A, 11 months for 
arm B and 6.3 months for arm C. The median number of cycles was 4 
with range 1-6 cycles.
In general, the 3 regimens were well tolerated: Neutropenia (all grades) 
was encountered in 31.5 %, 47.7 %, and 15 %, thrombocytopenia was 
encountered in 5.2 %, 26 % and 5 % and anemia occurred in 31.5 
%, 34.8 % and 35 % in groups A, B and C respectively. As for non 
hematological toxicity, arm A and C had more tendency to neuropathy 
while arm B had tendency to hepatotoxicity but there were no statistical 
differences.
Conclusion: Our results showed that paclitaxel/cisplatin, gemcitabine/
cisplatin, and paclitaxel/gemcitabine combinations provide no signiﬁ-
cant difference in response, survival or toxicity. Treatment was well 
tolerated by the patients in the 3 different groups.
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Background: Combined chemoradiotherapy is now considered the 
standard of care in patients with unresectable stage III NSCLC. Despite 
the therapeutic advances that have been made during the last decenni-
um, there remains a need for better local and distal control of disease in 
patients with locally advanced NSCLC. At present it is not clear which 
combined modality approach provides optimal results (both in terms of 
survival and toxicity). 
In the present study we wanted to evaluate whether by combining a 
carboplatin-gemcitabine based induction chemotherapy with weekly 
cisplatin during standard thoracic radiotherapy, it is possible to obtain 
good efﬁcacy with minimal toxicity
Methods: Patients (PS 0-1) with unresectable stage III NSCLC were 
treated with 3 cycles of induction chemotherapy followed by chemo-ra-
diotherapy. The induction chemotherapy consisted of carboplatin (AUC 
5 on day 1) with gemcitabine (1200 mg/m2 on day 1 and 8) every 3 
weeks for 3 cycles. The chemo-radiotherapy consisted of cisplatin (30 
mg/m2 weekly) concomitant with conventional radiotherapy (2.0 Gy/
fraction, 5 fractions a week, up to a total dose of 60 Gy). The primary 
endpoint of this phase II trial was a survival rate at 2 years of >35%.
Results: Between February 2003 and November 2005, 45 patients 
were enrolled: The demographics were as follows: 34/11 male/female, 
14/30 stage IIIA/IIIB, median age 62 y (range 41-81 y), 42% squamous 
cell and 33% adenocarcinoma. All patients received at least one cycle 
of induction chemotherapy: 7% only 1 cycle, 7% 2 cycles and 87% all 
3 cycles. Chemoradiotherapy was started in 36 patients. Median total 
radiation dose and duration was 60 Gy and 43 days.
Grade 3/4 toxicities during chemotherapy were: neutropenia (36%), 
thrombocytopenia (18%), febrile neutropenia (1%), rash (1%), eleva-
tion of transaminases (1%) and constipation (1%). The effect of the 
treatment on the pulmonary function is summarized in the folowing 
table:
 Baseline Post-chemo
Post- 
chemoradio
Follow-up at 
6 months
Follow-up 
at 12 months
Mean FEV1 (L) 2.26 2.42 2.48 2.33 2.27
Mean FVC (L) 3.19 3.41 3.14 3.32 3.05
Mean DLCO (%) 67.7 60.4 60.7 64.2 65.4
The overall response rate was 31% (2% CR, 29% PR) following induc-
tion chemotherapy, and 58% (2% CR, 56% PR) at the end of treatment. 
With a median follow-up of 14.4 months (range 1-35 months), the 
median progression-free survival is 10.6 months. The overall 1- and 
2-year survivals are 61% and 39%. 
Conclusions: The preliminary results from this phase II trial showed 
that induction chemotherapy with carboplatin and gemcitabine fol-
lowed by thoracic radiotherapy with concurrent weekly cisplatin is a 
well tolerated combined modality approach with promising overall 
survival in patients with unresectable stage III NSCLC.
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Involvement of N2 lymphatic structures, i.e. ipsilateral mediastinal 
lymph nodes in non-small cell cancer of the lung represents a very 
inhomogeneous disease, according to size, number, location, extension, 
and biologic features. Despite recent advances, the therapeutic strategy 
for stage IIIA subcategory remains unclear, particularly regarding the 
role of surgical resection. Controversial recent data suggest a potential 
impact of post-induction surgery speciﬁcally limited to patients who 
respond at the mediastinal level. Others make differences in approaches 
according to the location of mediastinal N2 involvement. Authors 
propose a simple decision-making algorithm based upon last advances 
in imaging, clinical trials, mediastinal status, response after induction, 
staging and re-staging new techniques, and current burning remaining 
questions. 
